Market Research Reports

Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

208pages
Published Date: 2014-07-01
 

Description


Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications. This report studies the current as well as future scenario of the diabetes diagnostic devices and drugs market globally. 

The diabetes diagnostic devices and drugs market has been segmented based on devices and drugs available for the treatment the disease. Based on device type, the market is segmented into diabetes diagnostic devices and insulin delivery devices. Diabetes diagnostic devices include analog blood meter, test strips, lancets and lancing devices, continuous glucose monitoring devices and others. The insulin delivery devices segment include insulin syringes, insulin pens, insulin pumps and insulin injectors.

Based on drugs, the market is segmented into insulin derivatives, oral anti-diabetes drugs and non-insulin injectable anti-diabetes drugs. The insulin derivatives segment is further categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. The oral anti-diabetes drugs segment includes various drugs classes such as sulphonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors, GPP-4 inhibitors and SGLT-2 inhibitors. The non-insulin injectable anti-diabetes drugs segment is segmented into GLP-1 analogs and Pramlintide. The market for these devices and drugs has been extensively analyzed based on demand for branded and generic products in each class of drugs and devices. Rising prevalence of diabetic population across various regions of the world, pipeline products from each class, rising preference of patients and healthcare professionals toward technologically advanced monitoring and insulin delivery devices is driving the growth of the diabetes diagnostic devices and drugs market. 

The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2013 to 2019, considering 2012 as the base year. The diabetes devices and drugs market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. 

Geographically, the diabetes diagnostic devices and drugs market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019, along with the CAGR (%) for the forecast period 2013 to 2019. The diabetes diagnostic devices and drugs market study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises a qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis and market attractiveness analysis. In addition, thorough analyses of various events, which occurred in the past five years and are expected to occur during forecast period, are also provided in the market overview section of the report. In this section, the major events, which affected the market and are expected to affect the market are studied. Further, value chain analysis (VCA) for drugs and devices is also provided, which highlights the major stages of the development of drugs and devices. The entire section of market overview plays an important role in understanding the market on a global level.

The diabetes devices and drugs market report also provides a highlight of the competitive landscape of the market wherein the market share analysis of the leading players in the diabetes devices and drugs market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the diabetes devices and drugs market such as Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Company Limited. Market players are profiled based on attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments.

The global diabetes devices and drugs market is segmented into the following categories:
  • Global Diabetes Devices Market, by Devices
    • Diabetes Monitoring and diagnostic devices
      • Analog glucose meter
      • Glucose Test strips
      • Lancets and Lancing devices
      • Continuous glucose monitoring devices
      • Others
    • Insulin Delivery Devices
      • Insulin Syringes
      • Insulin Pens
      • Insulin Pumps
      • Insulin Injectors
  • Global Diabetes Drugs Market, by Therapy
    • Insulin
      • Short-acting insulin derivatives
      • Intermediate-acting insulin derivatives
      • Long-acting insulin derivatives
      • Rapid-acting insulin derivatives
      • Premixed insulin derivatives
    • Oral anti-diabetes drugs class
      • Sulphonylureas
      • Biguanides
      • Meglitinides
      • Thiazolidinediones
      • Alpha-glucosidase inhibitors
      • DPP-4 inhibitors
      • SGLT-2 inhibitors
    • Non-insulin injectable anti-diabetes drugs
      • GLP-1 analogs
  • Global Diabetes Drugs Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Table of Contents



Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Sources
              1.3.1.1 Secondary Research
              1.3.1.2 Primary Research
      1.3.2 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Diabetes Devices and Drugs Market (2012 & 2019) 
2.2 Market Snapshot: Global Diabetes Devices Market (2012 & 2019) 
2.3 Global Diabetes Devices Market, by Types, 2012 (USD Million) 
2.4 Market Snapshot: Global Diabetes Drugs Market (2012 & 2019) 
2.5 Global Diabetes Drugs Market, by Drug Therapy, 2012 (USD Million) 
2.6 Competitive Analysis: Global Diabetes Devices and Drugs Market, By Geography, 2012 & 2019 (Value %)

Chapter 3 Disease Overview: Diabetes
3.1 Overview
3.2 Classification
3.3 Symptoms
3.4 Causes
3.5 Risk Factors
3.6 Chronic diseases associated with diabetes
3.7 Diagnosis
3.8 Flow Chart of Approach of Diabetes Management
3.9 Management
      3.9.1 Non-medicinal aspects of diabetes management
              3.9.1.1 Diet
              3.9.1.2 Weight Management
              3.9.1.3 Exercise
              3.9.1.4 Sleep management
      3.9.2 Medicinal Management
               3.9.2.1 Insulin
               3.9.2.2 Oral anti-diabetes drugs class
               3.9.2.3 Non-insulin injectable anti-diabetes drugs
3.10 Standard Glucose levels for Diabetic Patients

Chapter 4 Market Overview
4.1 Overview
4.2 Market Drivers
      4.2.1 Global rise in diabetic population expected to propel diabetes market
      4.2.2 Extensive R&D activities bring turnaround changes in the diabetes market
      4.2.3 Chronic diseases associated with diabetes fuels self-monitoring and insulin delivery devices market
      4.2.4 Technological innovations are the market boosters
      4.2.5 Pricing strategies played by key players bring strong changes in the global market
4.3 Market Restraints
      4.3.1 Patent expiry depletes profit of market
      4.3.2 High cost of diagnosis and treatment
      4.3.3 Unfavorable reimbursement policies
      4.3.4 Hard entry barriers demotivate new players to enter the market
4.4 Market Opportunities
      4.4.1 Development of non-invasive diabetes diagnostic and drug delivery devices augments the market growth
      4.4.2 Strong pipeline and development of molecules from newer class of diabetes drugs provide a ladder for growth
      4.4.3 Development of new formulations of insulin offer new market leads
4.5 Porter’s Five Force Analysis of the Global Diabetes Devices Market
      4.5.1 Bargaining power of suppliers
      4.5.2 Bargaining power of buyers
      4.5.3 Threat of substitutes
      4.5.4 Threat of new entrants
      4.5.5 Competitive rivalry
4.6 Porter’s Five Force Analysis of the Global Diabetes Drugs Market
      4.6.1 Bargaining power of suppliers
      4.6.2 Bargaining power of buyers
      4.6.3 Threat of new entrants
      4.6.4 Threat of substitutes
      4.6.5 Competitive rivalry
4.7 Event Impact Analysis
      4.7.1 Impact of positive events on diabetes devices and drugs Market
      4.7.2 Impact of negative events on diabetes devices and drugs market
4.8 Value Chain Analysis for Diabetes Drugs Market
4.9 Value Chain Analysis for Diabetes Devices Market
4.10 Market Attractiveness Analysis: Global Diabetes Devices and Drugs Market, by Geography

Chapter 5 Diabetes Devices Market, by Device Types
5.1 Overview
      5.1.1 Global Diabetes Devices Market Revenue, by Device Types, 2011 – 2019 (USD Million) 
5.2 Glucose Monitoring and Diagnostic Devices
      5.2.1 Global Glucose Monitoring and Diagnostic Devices Market Revenue, by Types, 2011 – 2019 (USD Million) 
      5.2.2 Lancets
              5.2.2.1 Global Lancets Market Revenue, 2011 – 2019 (USD Million) 
      5.2.3 Analog Glucose Meter
              5.2.3.1 Global Analog Glucose Meters Market Revenue, 2011 – 2019 (USD Million) 
      5.2.4 Glucose Test Strips
              5.2.4.1 Global Glucose Test Strips Market Revenue, 2011 – 2019 (USD Million) 
      5.2.5 Continuous Glucose Monitoring Devices (CGM) 
              5.2.5.1 Global Continuous Glucose Monitoring (CGM) Devices Market Revenue, 2011 – 2019 (USD Million) 
      5.2.6 Others
              5.2.6.1 mHealth Blood Glucose Monitors
              5.2.6.2 Glycated Hemoglobin Testing Products (Hemoglobin A1c Testing Kit) 
              5.2.6.3 Urine Glucose/Metabolite Monitoring Strips
              5.2.6.4 Global Others Devices Market Revenue, 2011 – 2019 (USD Million) 
5.3 Insulin Delivery Devices
      5.3.1 Global Insulin Delivery Devices Market Revenue, by Types, 2011 – 2019 (USD Million) 
      5.3.2 Insulin Syringes
              5.3.2.1 Global Insulin Syringes Market Revenue, 2011 – 2019 (USD Million) 
      5.3.3 Insulin Pens
              5.3.3.1 Global Insulin Pens Market Revenue, 2011 – 2019 (USD Million) 
      5.3.4 Insulin Pumps
              5.3.4.1 Global Insulin Pumps Market Revenue, 2011 – 2019 (USD Million) 
      5.3.5 Insulin Injectors
              5.3.5.1 Global Insulin Injectors Market Revenue, 2011 – 2019 (USD Million) 

Chapter 6 Global Diabetes Drugs Market, by Drug Therapy
6.1 Overview
      6.1.1 Global Diabetes Drugs Market Revenue, by Drug Therapy, 2011 – 2019 (USD Million) 
      6.1.2 Comparative Analysis: Global Diabetes Drugs Market Revenue, by Drug Therapy, 2012 & 2019 (Value %)
6.2 Oral Anti-Diabetes Drugs (OADs) 
      6.2.1 Mechanism of action for different OAD Classes
      6.2.2 Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2011 – 2019 (USD Million) 
      6.2.3 Comparative Analysis: Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
      6.2.4 Sulphonylureas
              6.2.4.1 Global Sulphonylureas Market Revenue, 2011 – 2019 (USD Million) 
      6.2.5 Meglitinides
               6.2.5.1 Global Meglitinides Market Revenue, 2011 – 2019 (USD Million) 
      6.2.6 Biguanides
              6.2.6.1 Global Biguanides Market Revenue, 2011 – 2019 (USD Million) 
      6.2.7 Thiazolidinediones (TZDs) 
              6.2.7.1 Global Thiazolidinediones Market Revenue, 2011 – 2019 (USD Million) 
      6.2.8 Alpha-Glucosidase Inhibitors
              6.2.8.1 Global Alpha-Glucosidase Inhibitors Market Revenue, 2011 – 2019 (USD Million) 
      6.2.9 Gliptins or DPP-4 Inhibitors
              6.2.9.1 Global DPP-4 Inhibitors Market Revenue, 2011 – 2019 (USD Million) 
              6.2.9.2 Pipeline Analysis
                          6.2.9.2.1 MK-3102 (Omarigliptin) 
      6.2.10 Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
                6.2.10.1 Mechanism action of SGLT2 Inhibitors
                6.2.10.2 Global Sodium Glucose Co-Transporter 2 Market Revenue, 2011 – 2019 (USD Million) 
                6.2.10.3 Pipeline Analysis
                             6.2.10.3.1 Ertugliflozin
                             6.2.10.3.2 Jardiance (Empagliflozin) 
6.3 Non-Insulin Injectable Drugs
      6.3.1 GLP-1 Agonists
      6.3.2 Global GLP-1 Agonists Market Revenue, 2011 – 2019 (USD Million) 
      6.3.3 Pipeline Analysis
              6.3.3.1 Dulaglutide
              6.3.3.2 Semaglutide (NN9535) 
              6.3.3.3 LATIN T1D(NN9211) 
              6.3.3.4 Tanzeum (Albiglutide) 
6.4 Insulin
      6.4.1 Characteristics of type of Insulin
      6.4.2 Global Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million) 
      6.4.3 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action, 2012 & 2019 (Value %)
      6.4.4 Short-Acting Insulin
              6.4.4.1 Global Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
      6.4.5 Rapid-Acting Insulin
              6.4.5.1 Global Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
              6.4.5.2 Pipeline Analysis
                         6.4.5.2.1 Afrezza
                         6.4.5.2.2 NN1218 (FIAsp) 
      6.4.6 Long-Acting Insulin
              6.4.6.1 Global Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
              6.4.6.2 Pipeline Analysis
                         6.4.6.2.1 LY2605541(Novel Basal Insulin Analog) 
                         6.4.6.2.2 LY2963016 (Long acting basal insulin) 
                         6.4.6.2.3 MK-1293 (Sustained release insulin analog) 
                         6.4.6.2.4 U-300 (Toujeo) 
                          6.4.6.2.5 IDegLira (Xultophy) 
      6.4.7 Intermediate-Acting Insulin
              6.4.7.1 Global Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
      6.4.8 Premixed Insulin
              6.4.8.1 Global Premixed Insulin Market Revenue, 2011 – 2019 (USD Million) 

Chapter 7 Diabetes Devices and Drugs Market Revenue, by Geography
7.1 Overview
      7.1.1 Global Diabetes Devices and Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million) 
7.2 North America
      7.2.1 North America Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
7.3 Europe
      7.3.1 Europe Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
7.4 Asia-Pacific
      7.4.1 Asia-Pacific Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
7.5 Rest of the World (RoW) 
      7.5.1 Global RoW Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 

Chapter 8 Competitive Landscape
8.1 Market Share Analysis, Global Glucose Monitoring and Diagnostic Devices, by Key Players, 2012 (%)
      8.1.1 Market Share Analysis, Global Glucose Montoring and Diagnostic Devices Market, 2012 (Value %)
8.2 Market Share Analysis, Global Insulin Delivery Devices, by Key Players, 2012 (%)
      8.2.1 Market Share Analysis, Global Insulin Delivery Devices Market, 2012 (Value %)
8.3 Market Share Analysis, Global Diabetes Drugs, by Key Players 2012 (%)
      8.3.1 Market Share Analysis, Global Diabetes Drugs Market, 2012 (Value %)

Chapter 9 Recommendations
9.1 Development of formulations that can be administered by different routes
9.2 Development of combination formulations
9.3 Focus on emerging markets
9.4 Overcoming technical incompatibilities
9.5 Development of technically innovative devices to overcome the limitations of existing devices
9.6 Development of cost-effective products

Chapter 10 Company Profiles
10.1 Abbott Laboratories, Inc. 
      10.1.1 Company Overview
      10.1.2 Financial Overview
      10.1.3 Product Portfolio
      10.1.4 Business Strategies
      10.1.5 Recent Developments
10.2 AstraZeneca plc
      10.2.1 Company Overview
      10.2.2 Financial Overview
      10.2.3 Product Portfolio
      10.2.4 Business Strategies
      10.2.5 Recent Developments
10.3 B. Braun Melsungen AG
      10.3.1 Company Overview
      10.3.2 Financial Overview
      10.3.3 Product Portfolio
      10.3.4 Business Strategies
      10.3.5 Recent Developments
10.4 Bayer HealthCare AG
      10.4.1 Company Overview
      10.4.2 Financial Overview
      10.4.3 Product Portfolio
      10.4.4 Business Strategies
      10.4.5 Recent Developments
10.5 Becton, Dickinson & Company
      10.5.1 Company Overview
      10.5.2 Financial Overview
      10.5.3 Product Portfolio
      10.5.4 Business Strategies
      10.5.5 Recent Developments
10.6 Boehringer Ingelheim GmbH
      10.6.1 Company Overview
      10.6.2 Financial Overview
      10.6.3 Product Portfolio
      10.6.4 Business Strategies
      10.6.5 Recent Development
10.7 DexCom, Inc. 
      10.7.1 Company Overview      
      10.7.2 Financial Overview
      10.7.3 Product Portfolio
      10.7.4 Business Strategies
      10.7.5 Recent Developments
10.8 Eli Lilly and Company
      10.8.1 Company Overview
      10.8.2 Financial Overview
      10.8.3 Product Portfolio
      10.8.4 Business Strategies
      10.8.5 Recent Developments
10.9 F. Hoffmann-La Roche Ltd. 
      10.9.1 Company Overview
      10.9.2 Financial Overview
      10.9.3 Product Portfolio
      10.9.4 Business Strategies
      10.9.5 Recent Developments
10.10 GlaxoSmithKline plc
      10.10.1 Company Overview
      10.10.2 Financial Overview
      10.10.3 Product Portfolio
      10.10.4 Business Strategies
      10.10.5 Recent Developments
10.11 Johnson & Johnson
      10.11.1 Company Overview
      10.11.2 Financial Overview
      10.11.3 Product Portfolio
      10.11.4 Business Strategies
      10.11.5 Recent Developments
10.12 Lupin Limited
      10.12.1 Company Overview
      10.12.2 Financial Overview
      10.12.3 Product Portfolio
      10.12.4 Business Strategies
      10.12.5 Recent Developments
10.13 Medtronic, Inc. 
      10.13.1 Company Overview
      10.13.2 Financial Overview
      10.13.3 Product Portfolio
      10.13.4 Business Strategies
      10.13.5 Recent Developments
10.14 Merck & Co., Inc. 
      10.14.1 Company Overview
      10.14.2 Financial Overview
      10.14.3 Product Portfolio
      10.14.4 Business Strategies
      10.14.5 Recent Developments
10.15 Novartis International AG
      10.15.1 Company Overview
      10.15.2 Financial Overview
      10.15.3 Product Portfolio
      10.15.4 Business Strategies
      10.15.5 Recent Developments
10.16 Novo Nordisk A/S
      10.16.1 Company Overview
      10.16.2 Financial Overview
      10.16.3 Product Portfolio
      10.16.4 Business Strategies
      10.16.5 Recent Developments
10.17 Sanofi
      10.17.1 Company Overview
      10.17.2 Financial Overview
      10.17.3 Product Portfolio
      10.17.4 Business Strategies
      10.17.5 Recent Developments
10.18 Takeda Pharmaceutical Company Limited
      10.18.1 Company Overview
      10.18.2 Financial Overview
      10.18.3 Product Portfolio
      10.18.4 Business Strategies
      10.18.5 Recent Development

List of Figures

FIG. 1 Diabetes Devices Market: Market Segmentation
FIG. 2 Diabetes Drugs Market: Market Segmentation
FIG. 3 Global Diabetes Devices Market, by Types, 2012 (USD Million) 
FIG. 4 Global Diabetes Drugs Market, by Drug Therapy, 2012 (USD Million) 
FIG. 5 Comparative Analysis: Global Diabetes Devices and Drugs Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 6 Flow Chart of Approach of Diabetes Management
FIG. 7 Pipeline Analysis: Diabetes Drugs under pipeline studies according to  phases of clinical trials: 2013
FIG. 8 Porter’s Five Force Analysis: Global Diabetes Devices Market
FIG. 9 Porter’s Five Force Analysis: Global Diabetes Drugs Market
FIG. 10 Value Chain Analysis for Diabetes Drugs Market
FIG. 11 Value Chain Analysis for Diabetes Devices Market
FIG. 12 Market Attractiveness Analysis: Global Diabetes Devices and Drugs Market, by Geography
FIG. 13 Global Lancets Market Revenue, 2011 – 2019 (USD Million) 
FIG. 14 Global Analog Glucose Meters Market Revenue, 2011 – 2019 (USD Million) 
FIG. 15 Global Glucose Test Strips Market Revenue, 2011 – 2019 (USD Million) 
FIG. 16 Global Continuous Glucose Monitoring (CGM) Devices Market Revenue, 2011 – 2019 (USD Million) 
FIG. 17 Global Others Devices Market Revenue, 2011 – 2019 (USD Million) 
FIG. 18 Global Insulin Syringes Market Revenue, 2011 – 2019 (USD Million) 
FIG. 19 Global Insulin Pens Market Revenue, 2011 – 2019 (USD Million) 
FIG. 20 Global Insulin Pumps Market Revenue, 2011 – 2019 (USD Million) 
FIG. 21 Global Insulin Injectors Market Revenue, 2011 – 2019 (USD Million) 
FIG. 22 Comparative Analysis: Global Anti-Diabetes Drugs Market Revenue, by Drug Therapy, 2012 & 2019 (Value %)
FIG. 23 Mechanism of action for different OAD Classes
FIG. 24 Comparative Analysis: Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2012 & 2019 (Value %)
FIG. 25 Global Sulphonylureas Market Revenue, 2011 – 2019 (USD Million) 
FIG. 26 Global Meglitinides Market Revenue, 2011 – 2019 (USD Million) 
FIG. 27 Global Biguanides Market Revenue, 2011 – 2019 (USD Million) 
FIG. 28 Global Thiazolidinediones Market Revenue, 2011 – 2019 (USD Million) 
FIG. 29 Global Alpha-Glucosidase Inhibitors Market Revenue, 2011 – 2019 (USD Million) 
FIG. 30 Global DPP-4 Inhibitors Market Revenue, 2011 – 2019 (USD Million) 
FIG. 31 Global MK-3102 Market Revenue, 2016 – 2019 (USD Million) 
FIG. 32 Mechanism action of SGLT2 Inhibitors
FIG. 33 Global Sodium Glucose Co-Transporter 2 Market Revenue, 2011 – 2019 (USD Million) 
FIG. 34 Global Ertugliflozin Market Revenue, 2017 – 2019 (USD Million) 
FIG. 35 Global Jardiance Market Revenue, 2015 – 2019 (USD Million) 
FIG. 36 Global GLP-1 Agonists Market Revenue, 2011 – 2019 (USD Million) 
FIG. 37 Global Dulaglutide Market Revenue, 2015– 2019 (USD Million) 
FIG. 38 Global Semaglutide Market Revenue, 2016 – 2019 (USD Million) 
FIG. 39 Global LATIN T1D Market Revenue, 2016– 2019 (USD Million) 
FIG. 40 Global Tanzeum Market Revenue, 2014 – 2019 (USD Million) 
FIG. 41 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action 2012 & 2019 (Value %)
FIG. 42 Global Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
FIG. 43 Global Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
FIG. 44 Global Afrezza Market Revenue, 2015 – 2019 (USD Million) 
FIG. 45 Global NN1218 Market Revenue, 2016 – 2019 (USD Million) 
FIG. 46 Global Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
FIG. 47 Global LY2605541 Market Revenue, 2015 – 2019 (USD Million) 
FIG. 48 Global LY2963016 Market Revenue, 2014 – 2019 (USD Million) 
FIG. 49 Global MK-1293 Market Revenue , 2016 – 2019 (USD Million) 
FIG. 50 Global U-300 Market Revenue, 2015 – 2019 (USD Million) 
FIG. 51 Global IDegLira Market Revenue, 2014 – 2019 (USD Million) 
FIG. 52 Global Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million) 
FIG. 53 Global Premixed Market Revenue, 2011 – 2019 (USD Million) 
FIG. 54 North America Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
FIG. 55 Europe Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
FIG. 56 Asia-Pacific Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
FIG. 57 Rest of the World (RoW) Diabetes Devices and Drugs Market Revenue, 2011 – 2019 (USD Million) 
FIG. 58 Market Share Analysis, Global Glucose Montiring and Diagnostic Devices Market, 2012 (Value %)
FIG. 59 Market Share Analysis, Global Insulin Delivery Devices Market, 2012 (Value %)
FIG. 60 Market Share Analysis, Global Diabetes Drugs Market, 2012 (Value %)
FIG. 61 Abbott Laboratories, Inc.: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 62 AstraZeneca plc: Annual Revenue 2011 – 2013 (USD Million) 
FIG. 63 B Braun Melsungen AG: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 64 Bayer HealthCare AG: Annual Revenue: 2011 – 2013 (USD Million) 
FIG. 65 Becton Dickinson & Company: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 66 Boehringer Ingelheim GmbH: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 67 DexCom, Inc.: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 68 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 69 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 70 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 71 Johnson & Johnson: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 72 Lupin Limited: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 73 Medtronic, Inc.: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 74 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 75 Novartis International AG: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 76 Novo Nordisk A/S.: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 77 Sanofi: Annual Revenue, 2011 – 2013 (USD Million) 
FIG. 78 Takeda Pharmaceutical Company Limited: Annual Revenue: 2011 – 2013 (USD Million) 

List of Tables

TABLE 1 Market Snapshot: Global Diabetes Devices and Drugs Market (2012 & 2019) 
TABLE 2 Market Snapshot: Global Diabetes Devices Market (2012 & 2019) 
TABLE 3 Market Snapshot: Global Diabetes Drugs Market (2012 & 2019) 
TABLE 4 Number of People with Diabetes (20 Years - 79 years), by Country/Territory, 2013 (Millions) 
TABLE 5 Global Diabetes Devices Market Revenue, by Device Types, 2011 – 2019 (USD Million) 
TABLE 6 Global Glucose Monitoring and Diagnostic Devices Market Revenue, by Types, 2011 – 2019 (USD Million) 
TABLE 7 Global Insulin Delivery Devices Market Revenue, by Types, 2011 – 2019 (USD Million) 
TABLE 8 Global Diabetes Drugs Market Revenue, by Drug Therapy, 2011 – 2019 (USD Million) 
TABLE 9 Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2011 – 2019 (USD Million) 
TABLE 10 Global Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million) 
TABLE 11 Global Diabetes Devices and Drugs Market Revenue, by Geography, 2011 – 2019 (USD Million) 

Enquiry Before Buying


Free Market Analysis


Diabetes is a group of metabolic disorders in which pancreas is not able to produce enough insulin (sugar metabolizing hormone) (type-1) or the body develops a resistance to produce insulin and is not able to utilize the produced insulin (type-2). This condition triggers various malignancies and diseases. Diabetes market is a consolidated market and the demand for various advanced devices and medicines is increasing steadily, owing to exponential growth in the prevalence of diabetes across the globe. This report is focused towards identifying the current scenario as well as the future market potential for diabetes drugs and devices globally.

The global diabetes devices and drugs market is segmented into two segments, namely; diabetes devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps and insulin injectors. The second segment of the market, that is, drugs class is fragmented into insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs. Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Oral anti-diabetes drugs are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors, thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes drugs. 

Out of all the above mentioned diagnostic and monitoring devices, continuous glucose monitoring devices segment is expected to grow at a CAGR of 6.6% from 2013 to 2019. Insulin pen is a rapidly growing segment in the global insulin delivery devices market. The rising population of diabetic patients across the globe is the most important driver of the market, followed by extensive R&D practices. According to International Diabetes Federation (IDF), as of 2013, around 382 million people were diagnosed with diabetes, and the number is expected to grow to 592 million by the end of 2035. This rise in diabetic population propels the market growth. Further, due to extensive R&D practices in drugs and devices, large numbers of drugs (around 180) are under pipeline studies. Hence, the market is augmented to grow steadily during the forecast period 2013 – 2019. In addition, rising demand for SGLT2 inhibitors, DPP-IV inhibitors, GLP-1 agonists and long-acting insulin derivatives drive the market of drugs to higher end. In addition to existing drugs, drugs and formulations under pipeline studies (for example, U-300, Afrezza, Dulaglutide and others) are also considered and the forecast for these products is estimated considering their expected approval and commercialization years. 

Geographically, in this report, the diabetes devices and drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). Presently, the North American region is the largest market in the world, owing to the presence of large number of type-1 and type-2 diabetic patients, technological advancements and world-class medical infrastructure. However, Asia-Pacific region is considered as the most promising market during the forecast period 2013 to 2019. High incidence rate of diabetes, steady increase in medical expenditure, increased healthcare awareness towards self-monitoring and management of diabetes are some of the important factors supporting the growth of diabetes devices and drugs market in Asia-Pacific region.

Globally, the market for diabetes devices is dominated by selected number of players, namely; F. Hoffmann La Roche Ltd., LifeScan, Inc. (J&J), Abbott Diabetes Care, and Bayer AG. In addition to this, some other important players that offer an important contribution to the total diabetes devices market include B Braun Melsungen AG and DexCom, Inc. Whereas, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, AstraZeneca plc, Merck, Inc., and Takeda Pharmaceutical Company Limited are the key players having presence in the global diabetes drugs market.

diabetes-devices-and-drugs-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research